Functional observational battery and motor activity in rats after single administration of two NHE 1 inhibitors.
Two tests, a functional observational battery (FOB) and measurement of motor activity, have been used to screen the two NHE inhibitors EMD 96785 and EMD 125021 for neurobehavioral effects. These two NHE inhibitors, which exhibit a marked selectivity for the NHE 1 isoform, are under development in the research laboratories of Merck KGaA. NHE inhibitors are developed for the treatment of acute myocardial infarction and chronic heart failure. In prior studies with EMD 96785 and EMD 125021, clinical symptoms, such as uncoordinated movements and weakness of the hindlimbs, were detected in rats. The aim of this study was the evaluation of clinical findings in more detail using a FOB and measurement of motor activity in 96 female rats. The time course and reversibility of the adverse effects were investigated. The animals were treated with EMD 96785 or EMD 125021 by intravenous injection at a single dose of 100 mg/kg and four different time points (2 h, 1 day, 7 days and 21 days after treatment) were chosen for the clinical examination. This neurobehavioral test battery clearly detected neurological activity and defined time-course characteristics after treatment with EMD 96785 or EMD 125021. The various clinical parameters were grouped into functional-related domains and most alterations were seen in the domains of central nervous system and neuromuscular system. The most prominent clinical findings were seen with the pharmacologically more potent NHE inhibitor EMD 125021 when compared to EMD 96785. The clinical symptoms were proven to be reversible by 7 days after the single treatment for both compounds.
Hübler
Nicole
N
Merck KGaA, Institute of Toxicology, Frankfurter Strasse 250, Darmstadt, 64293 Germany.
Gottschling
Barbara
B
Jacobs
Maren
M
von Landenberg
Friedrich
F
Hewicker-Trautwein
Marion
M
D000818:Animals; D001259:Ataxia / Q000139:chemically induced; D001522:Behavior, Animal / Q000187:drug effects* / Q000502:physiology; D001831:Body Temperature / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical / Q000379:methods; D005260:Female; D005684:Gait / Q000187:drug effects; D006146:Guanidines / Q000008:administration & dosage / Q000493:pharmacokinetics; D018737:Hand Strength; D006614:Hindlimb / Q000187:drug effects; D007275:Injections, Intravenous; D009043:Motor Activity / Q000187:drug effects* / Q000502:physiology; D011187:Posture; D051381:Rats; D017208:Rats, Wistar; D012025:Reflex, Pupillary / Q000187:drug effects / Q000502:physiology; D000074082:Sodium-Hydrogen Exchanger 1; D017923:Sodium-Hydrogen Exchangers / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000493:pharmacokinetics; D019956:Stereotypic Movement Disorder / Q000139:chemically induced; D013450:Sulfones / Q000008:administration & dosage / Q000493:pharmacokinetics; D013997:Time Factors
D006146:Guanidines; C452850:Slc9a1 protein, rat; D000074082:Sodium-Hydrogen Exchanger 1; D017923:Sodium-Hydrogen Exchangers; D013450:Sulfones; C118397:eniporide